Harvard Bioscience Announces Reverse Stock Split
Rhea-AI Summary
Harvard Bioscience (NASDAQ: HBIO) announced a 1-for-10 reverse stock split approved March 6, 2026, effective 4:30 p.m. ET on March 13, 2026, with post-split trading expected March 16, 2026.
The Reverse Split will convert every ten shares into one, reduce outstanding shares from ~44,719,894 to ~4,471,989, leave total authorized shares unchanged, and proportionally adjust options, warrants, and convertible securities.
No fractional shares will be issued; fractional holders will receive cash in lieu based on the March 13, 2026 closing price as adjusted for the split.
Positive
- Outstanding shares reduced ~90% to approximately 4,471,989
- Proportional adjustment to options, warrants, and convertible securities
Negative
- Total authorized shares will not be reduced
- Reverse split required to regain Nasdaq minimum bid price
Market Reaction – HBIO
Following this news, HBIO has declined 10.07%, reflecting a significant negative market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.49. This price movement has removed approximately $3M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
HBIO slipped 0.45% while peers showed mixed moves: BNGO (-0.71%), NXGL (-5.77%), MHUA (-27.18%) down, but RVP (+2.71%) and POCI (+1.02%) up. No clear sector-wide pattern, supporting this reverse split as a company-specific development.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Conference participation | Neutral | -4.3% | Management participation in KeyBanc virtual healthcare forum and webcast. |
| Feb 26 | Earnings call scheduled | Neutral | -0.5% | Announcement of Q4 2025 earnings release date and conference call details. |
| Feb 10 | Prelim earnings update | Positive | +13.4% | Preliminary Q4 2025 beat on revenue, high-end gross margin and EBITDA growth. |
| Jan 29 | Manufacturing restructuring | Positive | -6.7% | Project Viking consolidation with targeted long-term cost savings and near-term charges. |
| Dec 17 | Debt refinancing | Positive | +12.4% | Refinancing and new credit facility to repay debt and extend maturities. |
Positive financial or financing updates have often seen strong gains, while restructuring and routine announcements have sometimes met with negative reactions.
Over the last few months, HBIO reported preliminary Q4 2025 results with stronger revenue, margins and EBITDA, and the stock reacted positively. A December $40M refinancing also coincided with a double‑digit gain. In contrast, the manufacturing consolidation under “Project Viking” and scheduling/participation announcements around earnings calls and conferences saw negative or muted reactions. Today’s reverse split follows a period of sub‑$1 trading and prior proxy filings seeking flexibility to address Nasdaq’s minimum bid requirement.
Regulatory & Risk Context
An effective S-3 resale registration filed on Jan 30, 2026 covers up to 9,500,000 shares for sale by existing securityholders, including warrant and convertible loan shares. HBIO itself is not selling shares under this registration and would only receive up to $1.0 million if all registered warrants are exercised for cash.
Market Pulse Summary
The stock is dropping -10.1% following this news. A negative reaction despite the mechanical nature of a 1-for-10 reverse split would fit concerns often associated with such actions, especially given HBIO’s sub‑$1 price and prior Nasdaq deficiency notices. History shows mixed responses: strategic restructuring drew selling, while refinancing and strong prelim results saw gains. The unchanged authorized share count and an effective resale S-3 covering 9.5M shares underscore supply and structural risks that could weigh on sentiment.
Key Terms
reverse stock split financial
stock options financial
warrants financial
convertible securities financial
par value financial
AI-generated analysis. Not financial advice.
- Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026
HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value
The Reverse Split will legally take effect at 4:30 p.m. Eastern Time, on March 13, 2026. The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-10 Reverse Split will automatically convert every 10 current shares of the Company’s common stock into one share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on March 13, 2026.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 44,719,894 shares, to approximately 4,471,989 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company's transfer agent, Computershare Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
Additional information regarding the Reverse Stock Split is available in the Company's definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on January 30, 2026.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, statements concerning the sustainability of the Company’s ability to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, its capital structure, its lower near-term refinancing risk and path toward long-term deleveraging, expected future financial and operational performance, the strength of the Company’s market position, business model and anticipated macroeconomic conditions, and matters relating to our ability to continue as a going concern, fund our operations, or comply with the terms of our credit agreement. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission (“SEC”), as well as in the Company’s other filings with the SEC. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Harvard Bioscience Investor Inquiries:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ
What exactly is Harvard Bioscience's 1-for-10 reverse stock split (HBIO) and when is it effective?
How many Harvard Bioscience (HBIO) shares will be outstanding after the reverse split?
Will Harvard Bioscience shareholders need to take action to receive post-split HBIO shares?
How will Harvard Bioscience's outstanding options, warrants, and stock plans be affected by the HBIO reverse split?
Why did Harvard Bioscience (HBIO) implement the reverse stock split?
